论文部分内容阅读
目的 探讨多药耐药基因mdr 1及其蛋白P gp、凋亡抑制基因bcl 2及其相关蛋白P2 6 bcl 2在中、高度恶性非霍奇金淋巴瘤 (NHL)患者中表达的临床意义及潜在的预后价值。方法 应用免疫组织化学S P法对 6 0例NHL患者进行检测。结果 6 0例患者中P gp表达阳性者 15例 ,P2 6 bcl 2表达阳性者 2 5例。P gp和P2 6 bcl 2共同表达为阴性者的 3年生存率明显高于阳性表达者 (分别为48 48%和 15 .38% ,P =0 .0 38)。结论 P gp、P2 6 bcl 2表达与中、高度恶性NHL患者的化疗效果及预后相关。P gp和P2 6 bcl 2共同表达情况可作为预测中、高度恶性NHL患者化疗敏感性及预后的指标 ,对指导临床治疗具有意义
Objective To investigate the clinical significance of multidrug resistance gene mdr 1 and its protein P gp, apoptosis inhibitory gene bcl 2 and its related protein P2 6 bcl 2 in patients with moderate and high grade non-Hodgkin’s lymphoma (NHL) Potential prognostic value. Methods 60 cases of NHL were detected by immunohistochemical SP method. Results Fifty-five patients with positive P gp expression and 25 patients with positive P2 6 bcl 2 expression were found in 60 patients. The 3-year survival rates of patients with negative co-expression of P gp and P2 6 bcl 2 were significantly higher than those with positive expression (48 48% vs 15.38%, P = 0.038, respectively). Conclusion The expressions of P gp and P2 6 bcl 2 are correlated with the chemotherapy efficacy and prognosis in patients with moderate and high grade NHL. Pgp and P2 6 bcl 2 co-expression can be used as predictors of chemosensitivity and prognosis in patients with moderate and high-grade NHL, and it is significant to guide the clinical treatment